comparemela.com
Home
Live Updates
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial o
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial o
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose
Related Keywords
Spain ,
Australia ,
Madrid ,
Zurich ,
Züsz ,
Switzerland ,
United States ,
Schroder Adveq ,
Christoph Renner ,
Ludger Wess Ines Regina Buth ,
Company Contact ,
Mission Biocapital ,
Zurich Area ,
Immunos Therapeutics ,
Samsara Biocapital ,
Lightspeed Venture Partners ,
Pfizer Ventures ,
Biomed Partners ,
Ludger Wess ,
Business ,